EAAT3 emerges as a promising therapeutic target for preventing oxidative damage to neurons; a process relevant for multiple brain pathologies, in particular neurodegenerative disorders, epilepsy and ischemic stroke. The gene discussed is SLC1A1; the disease is ischemic stroke.